Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02520752 · ClinicalTrials.gov registry record · Phase 1
A DDI Study to Assess the Effect of INC280 on the PK of Midazolam and Caffeine in Patients With cMET-dysregulated Advanced Solid Tumors
A Phase 1 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 37
- Enrollment target
NCT02520752 is a Phase 1 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 37 participants.
The verdict
NCT02520752, a Phase 1 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 37 participants
- Enrollment target
Study Summary
Drg-drug Interaction (DDI) study to assess the effect of INC280 on the pharmacokinetics of midazolam and caffeine in patients with cMET-dysregulated advanced solid tumors
Interventions
- DRUG Midazolam
- DRUG Caffeine
- DRUG INC280
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2015-12-10 |
| Est. Completion | 2017-09-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02520752
The ClinicalTrials.gov registry entry for NCT02520752 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Midazolam is the first listed.
NCT02520752 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02520752 about?
NCT02520752 is a clinical study titled "A DDI Study to Assess the Effect of INC280 on the PK of Midazolam and Caffeine in Patients With cMET-dysregulated Advanced Solid Tumors". Drg-drug Interaction (DDI) study to assess the effect of INC280 on the pharmacokinetics of midazolam and caffeine in patients with cMET-dysregulated advanced solid tumors
What is the current status of trial NCT02520752?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 37 participants. The study started on 2015-12-10. Estimated completion is 2017-09-12.
What interventions are being tested in trial NCT02520752?
The interventions under investigation include: Midazolam (DRUG), Caffeine (DRUG), INC280 (DRUG).
Who is sponsoring clinical trial NCT02520752?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.